Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs

Pharmaceutical Research

Volumn 30, Issue 2, 2013, Pages 307-324

  Gao, Lei ^a   Liu, Guiyang ^a   Ma, Jianli ^a   Wang, Xiaoqing ^a   Zhou, Liang ^a   Li, Xiang ^a   Wang, Fang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

bioavailability; drug nanocrystals; oral drug delivery systems; redispersibility; solidification process

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; AMPHOTERICIN B; CILOSTAZOL; CYCLOSPORIN; DANAZOL; FENOFIBRATE; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN; NANOCRYSTAL; NANOPARTICLE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SOLUBILITY; FREEZE DRYING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MATERIAL COATING; MAXIMUM PLASMA CONCENTRATION; NANOANALYSIS; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; PARASITOSIS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SPRAY DRYING; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY;

EID: 84873428567     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0889-z     Document Type: Review

References (105)

1. Fasano A. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol. 1998;16(4):152-7.
2. Colombo P, Sonvico F, Colombo G, Bettini R. Novel platforms for oral drug delivery. Pharm Res. 2009;26(3):601-11.
3. Dandan L, Heming X, Baocheng T, Kun Y, Hao P, Shilin M, et al. Fabrication of carvedilol nanosuspensions through the anti-Solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability. AAPS PharmSciTech. 2012;13(1):295-304.
4. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000;11(S2):73-80.
5. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;60(2):90-9.
6. Lipinski C. Poor aqueous solubility - an industry wide problem in drug discovery. Am Pharm Rev. 2002;5(3):82-5.
7. Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J Control Release. 2010;141(3):300-2.
8. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm. 2006;62(1):3-16.
9. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785-96.
10. Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res. 2008;10(5):845-62.
11. Reed RG, Czekai DA, Bosch HW, Ryde NP, Ryde T. Small scale mill and methods thereof. United States Patent 2002; No. 6,431,478.
12. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
13. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631-44.
14. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 1989;51(1):9-17.
15. Böhm BHL, Müller RH. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm Sci Tech Today. 1999;2(8):336-9.
16. Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399(1-2):129-39.
17. Müller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1-3):151-70.
18. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113-20.
19. Hu J, Johnston KP, Williams RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm. 2004;30(3):233-45.
20. Junghanns JAH, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-310.
21. Ghosh S, Chiang P, Wahlstrom JL, Fujiwara H, Selbo JG, Roberds SL. Oral delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol. 2008;102(5):453-8.
22. Sigfridsson K, Nordmark A, Theilig S, Lindah A. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm. 2011;37(2):185-92.
23. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004;285(1-2):135-46.
24. Sigfridsson K, Forssén S, Holländer P, Skantze U, de Verdier J. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm. 2007;67(2):540-7.
25. Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, et al. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm. 2009;370(1-2):167-74.
26. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111(1-2):56-64.
27. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm. 2006;317(1):82-9.
28. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125(1):91-7.
29. Vogt M, Vertzoni M, Kunath K, Reppas C, Dressman JB. Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. Eur J Pharm Biopharm. 2008;68(2):338-45.
30. Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm. 2009;35(7):827-33.
31. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007;59(6):419-26.
32. Mou D, Chen H, Wan J, Xu H, Yang X. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm. 2011;413(1-2):237-44.
33. Vergote GJ, Vervaet C, Van Driessche I, Hoste S, De Smedt S, Demeester J, et al. In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. Int J Pharm. 2002;240(1-2):79-84.
34. Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm. 1995;125(2):309-13.
35. Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, et al. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm. 2005;31(3):319-29.
36. Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction for improvement of oral absorption absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm. 2009;35(12):1479-86.
37. Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm. 2011;404(1-2):231-7.
38. Sarkari M, Brown J, Chen X, Swinnea S, Williams III RO, Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm. 2002;243(1-2):17-31.
39. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchêne D. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm. 1997;44(1):25-31.
40. Duchêne D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm. 1997;44(1):15-23.
41. Dodou D, Breedveld P, Wieringa PA. Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. Eur J Pharm Biopharm. 2005;60(1):1-16.
42. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556-68.
43. Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int J Pharm. 2001;214(1-2):83-5.
44. Awaad A, Nakamura M, Ishimura K. Imaging of size-dependent uptake and identification of novel pathways in mouse Peyer's patches using fluorescent organosilica particles. Nanomedicine. 2012;8(5):627-36.
45. Lamprecht A, Koenig P, Ubrich N, Maincent P, Neumann D. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells. Nanotechnology. 2006;17(15):3673-80.
46. Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet. 1999;37 Suppl 2:13-23.
47. Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther. 2006;44(2):64-70.
48. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev. 1998;34(2-3):221-33.
49. Grama CN, Ankola DD, Ravi Kumar MNV. Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives. Curr Opin Colloid Interface Sci. 2011;16(3):238-45.
50. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13(12):1838-45.
51. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1-27.
52. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999;16(10):1550-6.
53. Burton L, Ying W, Gandhi R, West R, Huang C, Zhou S, et al. Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound. Int J Pharm. 2012;433(1-2):94-101.
54. Goole J, Lindley DJ, Roth W, Carl SM, Amighi K, Kauffmann JM, et al. The effects of excipients on transporter mediated absorption. Int Pharm. 2010;393(1-2):17-31.
55. Huang J, Si L, Jiang L, Fan Z, Qiu J, Li G. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm. 2008;356(1-2):351-3.
56. Wempe MF, Wright C, Little JL, Lightner JW, Large SE, Caflisch GB, et al. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS. Int J Pharm. 2009;3701-2:93-102.
57. Andes D. Minireview: in vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother. 2003;474:1179-786.
58. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;481:137-42.
59. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm. 2003;2541:73-5.
60. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm. 2006;3121-2:179-86.
61. Salzberg M, Pless M, Rochlitz C, Ambrus K, Scigalla P, Herrmann R. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance. Invest New Drugs. 2006;244:299-304.
62. Choi YK, Poudel BK, Marasini N, Yang KY, Kim JW, Kim JO, et al. Enhanced solubility and oral bioavailability of itraconazole by combining membrane emulsification and spray drying technique. Int J Pharm. 2012;4341-2:264-71.
63. Van Eerdenbrugh B, Vercruysse S, Martens JA, Vermant J, Froyen L, Van Humbeeck J, et al. Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions - a case study with itraconazole. Eur J Pharm Biopharm. 2008;702:590-6.
64. Badawi AA, El-Nabarawi MA, El-Setouhy DA, Alsammit SA. Formulation and stability testing of itraconazole crystalline nanoparticles. AAPS PharmSciTech. 2011;123:811-20.
65. Lai F, Pini E, Angioni G, Manca ML, Perricci J, Sinico C, et al. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur J Pharm Biopharm. 2011;793:552-8.
66. Ain-Ai A, Gupta PK. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int J Pharm. 2008;3511-2:282-8.
67. Guo Z, Pereira T, Choi O, Wang Y, Hahn HT. Surface functionalized alumina nanoparticle filled polymeric nanocomposites with enhanced mechanical properties. J Mater Chem. 2006;166:2800-8.
68. Mauludin R, Müller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm. 2009;3701-2:202-9.
69. Juhnke M, Märtin D, John E. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur J Pharm Biopharm. 2012;811:214-22.
70. Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm. 2008;3411:1209-18.
71. Wang BH, Zhang WB, Zhang W, Mujumdar AS, Huang LX. Progress in drying technology for nanomaterials. Dry Technol. 2005;231-2:7-32.
72. Chaubal MV, Popescu C. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm Res. 2008;2510:2302-8.
73. Kim S, Lee J. Effective polymeric dispersants for vacuum, convection and freeze drying of drug nanosuspensions. Int J Pharm. 2010;3971-2:218-24.
74. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;636:427-40.
75. Saez A, Guzmán M, Molpeceres J, Aberturas MR. Freeze drying of polycaprolactone and poly d, l-lactic-glycolic nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm. 2000;503:379-87.
76. Heng D, Ogawa K, Cutler DJ, Chan H, Raper JA, Ye L, et al. Pure drug nanoparticles in tablets: what are the dissolution limitations? J Nanopart Res. 2010;125:1743-54.
77. de Waard H, Hinrichs WL, Frijlink HW. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J Control Release. 2008;1282:179-83.
78. Lee J, Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release. 2006;1111-2:185-92.
79. Zhang D, Tan T, Gao L, Zhao W, Wang P. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm. 2007;335:569-75.
80. Gao L, Zhang D, Chen M, Zheng T, Wang S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm. 2007;3312:1332-9.
81. Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm. 2008;3551-2:321-7.
82. Kumar MP, Rao YM, Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr Nanosci. 2008;41:53-8.
83. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;451:77-83.
84. Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, et al. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm. 2007;3381-2:198-206.
85. Vogt M, Vertzoni M, Kunath K, Reppas C, Dressman JB. Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. Eur J Pharm Biopharm. 2008;682:338-45.
86. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;2991-2:167-77.
87. Dolenc A, Kristl J, Baumgartner S, Planinsek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;3761-2:204-12.
88. Möschwitzer J, Müller RH. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm. 2006;623:282-7.
89. Vergote GJ, Vervaet C, Van Driessche I, Hoste S, De Smedt S, Demeester J, et al. An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int J Pharm. 2001;2191-2:81-7.
90. Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm. 2011;4201:141-6.
91. Lee J. Drug nano- and microparticles processed into solid dosage forms: physical properties. J Pharm Sci. 2003;9210:2057-68.
92. Iskandar F, Gradon L, Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol. J Colloid Interface Sci. 2003;2652:296-303.
93. Sebhatu T, Angberg M, Ahlneck C. Assessment of the degree of disorder in crystalline solids. Int J Pharm. 1994;1012:237-47.
94. Aguiar AJ, Zelmer JE, Kinkel AW. Deaggregation behavior of a relatively insoluble substituted benzoic acid and its sodium salt. J Pharm Sci. 1967;5610:1243-52.
95. Sun C, Grant DJ. Effects of initial particle size on the tableting properties of l-lysine monohydrochloride dihydrate powder. Int J Pharm. 2001;2151-2:221-8.
96. Busignies V, Leclerc B, Porion P, Evesque P, Couarraze G, Tchoreloff P. Compaction behaviour and new predictive approach to the compressibility of binary mixtures of pharmaceutical excipients. Eur J Pharm Biopharm. 2006;641:66-74.
97. Takagi H, Kajiyama A, Yanagisawa M. Rapidly disintegrable pharmaceutical composition. United States Patent 2007; 7 189 415.
98. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;3641:64-75.
99. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. Drying of crystalline drug nanosuspensions - the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci. 2008;351-2:127-35.
100. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009;263:492-501.
101. Kipp JE. The role of solid nanoparticle technology in parenteral delivery of poorly water soluble drugs. Int J Pharm. 2004;2841-2:109-22.
102. Shubar HM, Lachenmaier S, Heimesaat MM, Lohman U, Mauludin R, Muller RH, et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efcacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. J Drug Target. 2011;192:114-24.
103. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization method. J Pharm Pharmacol. 2010;6211:1569-79.
104. Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behavior. Int J Pharm. 2009;3731-2:124-32.
105. Okumu A, DiMaso M, Löbenberg R. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm Res. 2008;2512:2778-85.